BATH & BODY WORKS, INC. (BBWI): what the price requires
The current priced-in claim for BATH & BODY WORKS, INC. (BBWI) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/BBWI
Headline
| Field | Value |
|---|---|
| Ticker | BBWI |
| Company | BATH & BODY WORKS, INC. |
| Current price | $20.31/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 7.0% |
| Operating margin today | 12.8% |
| Margin compression implied | -5.8pp |
| Multiple paid | 11x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.
Solve inputs: computed at a 8.1% cost of capital with 4% terminal growth over a 5-year stage.
Reconcile: at the x-ray's 9.3% required return this reads ~-2.4%/yr; the models below use their own rates.
How unusual the bet is: within-range (limited comparison data)
| Reference | Value |
|---|---|
| vs own history | -0.38σ |
| implied end-window share | 0% |
Valuation X-Ray
The price is supported by earnings-power and relative-multiple value, while growth-DCF lands below the price. A value/asset-supported name, not a pure growth bet.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | — | 0 | — |
| Earnings | 0.73x | 3 | justifies |
| Relative | 0.32x | 2 | justifies |
| Growth | 2.04x | 2 | expensive |
Families that justify the price: Earnings, Relative Families that call it expensive: Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.9%); the inversion above states its own rate.
Per-Model Detail (n=7)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $98.81 | 0.21x | no | FCF base $0.9B, growth -1% (input: historical growth), terminal g 0.5%, WACC 4.9%, 5yr projection |
| DCF Exit Multiple | Growth | $44.81 | 0.45x | no | Exit EV/EBITDA: 4.0x / 5.7x / 7.7x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $52.48 | 0.39x | yes | P/E 14.26x (blended: static sector reference 20x + trailing (TTM) 6x), scenarios: 12.1x / 14.3x / 16.4x (bear / base = reference held flat / bull), EV/EBITDA 10.69x |
| Simple DDM | Growth | $8.56 | 2.37x | yes | DPS $0.79, g=0.0% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3% |
| Two-Stage DDM | Growth | $11.95 | 1.70x | yes | Stage 1: -1% for 5yr, Stage 2: 3.5% perpetual |
| Simple Excess Return | Asset | — | — | no | — |
| Two-Stage Excess Return | Asset | — | — | no | — |
| Discounted Future Market Cap | Growth | $16.10 | 1.26x | no | Rev $7.2B, growth -1% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.7x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $122.35 | 0.17x | no | Normalized EBIT (5y avg op income, one-time charges added back) $1.43B × (1−21%) / WACC 4.9% → EPV (no growth) |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | $77.69 | 0.26x | yes | EBITDA $1.40B × sector EV/EBITDA 14.0x |
| FCF Yield | Earnings | $29.38 | 0.69x | yes | FCF $909.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $27.82 | 0.73x | yes | SBC-adj FCF $0.88B (FCF $0.91B − SBC $0.03B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $22.07 | 0.92x | yes | EPS $3.52 × (8.5 + 2×-0.5%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $53.80 | 0.38x | no | Revenue $7.25B × sector P/S 1.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $38.05 | 0.53x | no | EPS $3.52 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $3.1b |
| Net debt / NOPAT (after-tax) | 5.12x |
| Net debt / operating income (pre-tax) | 4.04x |
| Interest coverage | 2.7x |
| Share count CAGR (buyback) | -4.5% |
| Burning cash | no |
Bullet Takeaways
- Bath & Body Works is a vertically integrated fragrance and personal-care retailer the filing calls one of "the premier fragrance companies in the wor"ld, generating roughly $900 million of free cash flow but with sales slipping, down 3% to $1.4 billion in the first quarter.
- The biggest near-term risk is a shrinking top line plus debt: management guides full-year 2026 sales down 2.5% to 4.5%, while net debt sits near 2.7 times operating income, so the cheap multiple is the market pricing decline, not a bargain.
- What moves the stock next is whether new product categories revive growth under a new leadership team, with EPS guidance of $3.00 to $3.25 and a CFO search underway after the prior CFO departed in June.
Bull Case
The bull case begins with how far the price sits below where the valuation methods land. Nearly every lens values Bath & Body Works well above its current price: the peer-multiple read, the EV/EBITDA comparison, and the zero-growth free-cash-flow capitalization all land at a meaningful premium to the stock. At roughly 11 times operating income, the price sits below what even a steady 5% annual decline in operating profit would warrant. The market is pricing this business as if it is in structural decline, and the methods that simply capitalize its current cash generation say it is worth far more. That gap is the setup.
The reason the cash flow is real is the business model. Bath & Body Works is vertically integrated: it designs, sources, and sells its own fragrances, candles, and body-care products through its own stores and website, which is why it earns retail margins a typical reseller cannot. The filing describes the brand as "a well-known, beloved and broadly appealing brand, which allows us to target markets across the economic spectrum, across demographics and across the world." That brand throws off roughly $909 million of free cash flow on about $1.4 billion of quarterly sales, and the company converts a high share of earnings to cash because it does not carry the inventory risk or licensing costs of selling other people's brands.
Management is using that cash on the per-share math, which compounds value even without growth. The share count has been shrinking about 4.5% a year through buybacks, and the company pays a dividend, so each remaining share owns a larger slice of the cash flow every year. The first quarter beat expectations, with adjusted EPS of $0.32 against a $0.29 estimate, and the stock jumped on the print, a sign sentiment was set for worse. Candles, the signature category, were a bright spot with strong sell-through. The bull case is that a cash-rich, vertically integrated fragrance brand trading at 11 times operating income, buying back stock aggressively, does not need to grow to reward holders; it needs only to stop the methods from being right that it is in terminal decline.
Bear Case
The competitive and demand pressure on Bath & Body Works is the bear's clearest ground, and it shows up first in the products customers are walking away from. The body-care category, a core part of the assortment, declined mid-single digits in the first quarter, which management attributed to weak Holiday Traditions collections and consumer fatigue with a too-predictable lineup. That phrase is the whole problem: a fragrance retailer lives on novelty, and when customers tire of the same seasonal rotation, they simply buy less, or buy from someone newer. The fragrance and personal-care space is crowded with direct-to-consumer brands, beauty specialists, and mass retailers, and switching costs are zero.
The store-based model is a structural vulnerability the filing names directly. Bath & Body Works depends "more than some of our competitors on physical locations in retail centers. Therefore, declines in traffic to such locations may affect us more significantly than our competitors." Mall and shopping-center traffic has been in long-term decline, and a retailer more exposed to those locations than its rivals feels that erosion harder. The same filing warns that if the company "misjudge[s] the market for our products or any new product lines," it may not achieve growth, which is exactly the risk a fashion-and-fragrance business runs every season.
The declining top line meets a leveraged balance sheet, which is what turns a soft patch into a real concern. Management itself guides full-year 2026 net sales down 2.5% to 4.5%, so the company is not forecasting a return to growth; it is forecasting continued contraction. Against that, net debt sits near $3 billion, about 2.7 times operating income, with interest coverage around 4.2 times. A shrinking, leveraged retailer has less room to invest in the product refresh it needs, and the leadership is in transition, with the CFO having departed in June and a search underway. The bear case is that the cheap multiple is not a mispricing but an accurate read: a mall-dependent fragrance retailer with declining core categories, real debt, and management turnover, where the methods that value it higher all assume a stabilization the company itself is not guiding to.
Valuation
Bath & Body Works trades at about 11 times operating income, a multiple so low the price sits below what even a 5% annual decline in operating profit would warrant. The price is pricing in contraction, which on the surface looks like a low bar, until you read it against management's own guidance for full-year sales down 2.5% to 4.5%. The price and the company's outlook agree that the business is shrinking; the disagreement is only about how far and how fast.
The method spread is wide and tilts cheap. The peer-multiple lens lands well above the price, the EV/EBITDA comparison lands far above it, and the zero-growth free-cash-flow capitalization, which simply takes the current $909 million of free cash flow and values it with no growth at all, lands above the price as well. Only the dividend-discount methods, which build in the flat-to-declining payout trajectory, sit near or below the price. In plain terms, the methods that capitalize the current cash generation say the stock is worth substantially more, and the methods that extrapolate the decline say it is roughly fair. The buyer's question is which is right: if the cash flow holds anywhere near today's level, the price is too low; if the decline accelerates, the cheap multiple is justified.
Solvency is the constraint that sharpens the downside. Net debt of roughly $3 billion runs about 2.7 times operating income, with interest coverage around 4.2 times and roughly $820 million of liquid assets. That leverage is serviceable while free cash flow stays strong, but it limits flexibility if sales keep sliding, and it competes with the buyback for the same cash. The most decisive point for the valuation is the tension between the cash flow and the trajectory: at 11 times operating income the buyer is paid well to own a cash-generative brand, but the company is guiding to continued sales declines, so the bet is entirely on whether the cash flow stabilizes or whether the consumer fatigue and mall-traffic erosion that the bear names keep grinding it lower.
Catalysts
Bath & Body Works' first quarter of 2026 came in better than feared, which is why the stock reacted hard. Net sales fell 3% to $1.4 billion, but adjusted EPS of $0.32 beat the $0.29 estimate, and the shares surged roughly 13% on the print. Within the mix, home fragrance grew low single digits and candles were a bright spot on strong sell-through, while body care declined mid-single digits on weak seasonal collections and consumer fatigue with the assortment.
The guidance frames the year as a managed decline. The company reaffirmed full-year 2026 net sales down 4.5% to down 2.5%, with EPS of $3.00 to $3.25 and adjusted EPS of $2.40 to $2.65. The catalyst that matters is whether the product refresh and new categories under the company's 'Consumer First' strategy can stabilize the top line before the year-over-year comparisons get easier; each quarter's comparable-sales figure is the cleanest read.
Leadership transition is the overhang to watch. The chief financial officer stepped down in June 2026 with an interim CFO in place and an active search underway, while Daniel Heaf leads as CEO. Management changes at a company already trying to reverse a sales decline add execution uncertainty. The next earnings reports, with the comparable-sales trajectory against the down-2.5%-to-4.5% guide, the candle and body-care category trends, and any permanent CFO appointment, are the events that tell investors whether the business is stabilizing or whether the decline the price already assumes is deepening.
Peer Cohorts (Per Segment, With Filing Citations)
Bath & Body Works (consolidated) (reported)
- ULTA (Ulta Beauty, Inc.)
- (no filing in the citation store)
- SBH (SALLY BEAUTY HOLDINGS, INC.)
- (no filing in the citation store)
- VSCO (VICTORIA'S SECRET & CO.)
- (no filing in the citation store)
- WSM (WILLIAMS-SONOMA, INC.)
- (no filing in the citation store)
- SIG (SIGNET JEWELERS LIMITED)
- (no filing in the citation store)
- SVV (Savers Value Village, Inc.)
- (no filing in the citation store)
- BBY (BEST BUY CO., INC.)
- (no filing in the citation store)
- GME (GameStop Corp.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Bath & Body Works Q1 2026 results · Bath & Body Works FY2026 guidance · company financial data · Bath & Body Works leadership update, June 2026